2.54

3.42% -0.09

After Hours: 2.55 0.010 +0.39%

Lumos Pharma Inc (LUMO)

Overview News Price History Financials Discussions Forecast Stock Split

Lumos Pharma Inc stock is currently priced at $2.54, with a 24-hour trading volume of 7,451. It has seen a -3.42% decreased in the last 24 hours and a +0.79% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.51 pivot point. If it approaches the $2.79 resistance level, significant changes may occur.

Previous Close:

$2.63

Open:

$2.64

24h Volume:

7,451

Market Cap:

$20.62M

Revenue:

$2.74M

Net Income/Loss:

$-41.38M

P/E Ratio:

-0.5393

EPS:

-4.71

Net Cash Flow:

$-31.10M

1W Performance:

-12.41%

1M Performance:

+0.79%

6M Performance:

-16.99%

1Y Performance:

-21.85%

1D Range:

$2.42

$2.64

52W Range:

$2.01

$4.55

Lumos Pharma Inc Stock (LUMO) Company Profile

Name

Lumos Pharma Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

512 215 2630

Address

4200 Marathon Boulevard, Suite 200, Austin, TX

Employee

Twitter

@lumos_pharma

Next Earnings Date

2024-05-31

Latest SEC Filings

LUMO's Discussions on Twitter

Lumos Pharma Inc Stock (LUMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-21	Upgrade	Stifel	Hold → Buy
Dec-03-20	Initiated	Cantor Fitzgerald	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Aug-17-20	Resumed	ROTH Capital	Buy
Aug-04-20	Initiated	H.C. Wainwright	Buy

Lumos Pharma Inc Stock (LUMO) Latest News

Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies UK

Yahoo Movies UK

Earnings call: Lumos Pharma gears up for Phase 3 trial of LUM-201 By Investing.com - Investing.com Canada

Investing.com Canada

Lumos Pharma maintains shares price target, Outperform rating on LUM-201 potential - Investing.com Canada

Investing.com Canada

Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results - ForexTV.com

ForexTV.com

TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates - MSN

MSN

Lumos Pharma Inc Stock (LUMO) Financials Data

Lumos Pharma Inc (LUMO) Revenue 2024

LUMO reported a revenue (TTM) of $2.74 million for the quarter ending December 31, 2023, a +67.81% rise year-over-year.

Lumos Pharma Inc (LUMO) Net Income 2024

LUMO net income (TTM) was -$41.38 million for the quarter ending December 31, 2023, a -6.70% decrease year-over-year.

Lumos Pharma Inc (LUMO) Cash Flow 2024

LUMO recorded a free cash flow (TTM) of -$31.09 million for the quarter ending December 31, 2023, a -16.80% decrease year-over-year.

Lumos Pharma Inc (LUMO) Earnings per Share 2024

LUMO earnings per share (TTM) was -$5.08 for the quarter ending December 31, 2023, a -9.96% decline year-over-year.

Lumos Pharma Inc Stock (LUMO) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
McKew John C.	Chief Scientific Officer	Feb 06 '24	Sale	3.03	438	1,328	18,403
McKew John C.	Chief Scientific Officer	Aug 02 '23	Sale	3.21	3,407	10,919	18,707

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.